Denotes acquired investment
Denotes public company
KENAI THERAPEUTICS
Kenai is pioneering the development and manufacture of novel off-the-shelf induced pluripotent stem cell (iPSC) based therapies for the treatment of neurodegenerative disorders, including Parkinson’s disease.
VISIT SITE
LYTERIAN THERAPEUTICS
Lyterian is utilizing novel protein homeostasis mechanisms to degrade and therefore inhibit, genetically defined disease targets. Their initial focus will be on aggregated protein diseases, many of which are central to neurodegenerative disease.
VISIT SITE
KIMIA
Kimia's ATLAS platform combines high-throughput experimentation with machine learning to empower generative drug design. By combining ATLAS with gene editing, Kimia can identify novel targets amenable to therapeutic intervention and is creating a chemical atlas for treating oncology and immunological diseases.
VISIT SITE
ATAVISTIK BIO
Atavistik Bio is a pre-clinical stage biotechnology company pioneering the identification of allosteric small molecule-protein interactions that have the potential to lead to the discovery and future clinical development of first-in-class drug compounds within oncology and metabolic diseases.
VISIT SITE
CAJAL NEUROSCIENCE
Cajal Neuroscience is a drug discovery company focused on neurodegenerative disease. Cajal is inspired by the pioneering work of Nobel laureate Santiago Ramón y Cajal who illuminated the complexity of the brain by marrying art and science.
VISIT SITE
CASMA THERAPEUTICS
Casma Therapeutics is harnessing the autophagy-lysosome pathway to enhance the clearance of disease causing proteins, signaling complexes, aggregates, organelles and pathogens as well as mechanisms to activate lysosomal-mediated membrane repair in diseases such as muscular dystrophy.
VISIT SITE
CIRCLE PHARMA
Circle Pharma operates an indication-agnostic discovery engine for the development of cell permeable macrocyclic peptide therapeutics. Circle's discovery engine combines computational structure-based design with automated, fully synthetic chemistry.
VISIT SITE
EIKON THERAPEUTICS
Eikon Therapeutics is a new biopharmaceutical company employing the revolutionary technology of single molecule imaging at the intersection of chemistry, engineering and biology to discover novel treatments for life-threatening diseases.
VISIT SITE
HEXAGON BIO
Hexagon's interdisciplinary platform discovers evolutionarily refined small molecules and their protein targets directly from fungal genomes. Hexagon then develops these molecules into therapeutics to combat human disease.
VISIT SITE
INDUPRO
InduPro seeks to discover and redefine cell-surface interactions to modulate biological pathways driving human diseases. InduPro platforms integrate inherent protein proximity at the cell surface with the ability to manipulate protein pairings using innovative molecular engineering to create novel signaling pathways.
VISIT SITE
REMIX THERAPEUTICS
Remix Therapeutics is developing novel small molecule therapies designed to reprogram RNA processing and treat disease in entirely new ways. Remix's innovative therapeutic solutions has the potential to address disease drivers at their origin.
VISIT SITE
TR1X BIO
Tr1X is developing therapies intended to reset the immune system and promote tolerance. Our proprietary platform generates potent, targeted regulatory T cell-based products to cure immune and inflammatory diseases.
VISIT SITE
VELIA THERAPEUTICS
Velia is harnessing the therapeutic potential of a novel class of small human proteins, microproteins, which regulate biological functions vital to human health. Velia will discover and develop therapeutics targeting these potent regulators.
VISIT SITE
A2 BIOTHERAPEUTICS
A2 Biotherapeutics is an early-stage biotechnology company located in Southern California that develops novel medicines for serious illnesses. A2 utilizes an advanced targeting technology platform to increase the effectiveness of the body’s natural immune defenses.
VISIT SITE
ACCENT THERAPEUTICS
Accent Therapeutics is developing small molecule, precision cancer therapies in the emerging field of epitranscriptomics. By targeting cancer-linked RNA-modifying proteins (RMPs) with precision drugs, Accent is translating extraordinary, novel science into life-changing therapies for patients.
VISIT SITE
ESCIENT PHARMACEUTICALS
Escient Pharmaceuticals is advancing first-in-class G Protein-Coupled Receptor (GPCR)-targeted drugs to address serious, unserved medical needs across a broad range of therapeutic indications. Escient will initially pursue medicines for neuro-immuno-inflammatory and autoreactive diseases.
VISIT SITE
NURA BIO
Nura Bio (formerly Proneurotech) seeks to alter the course of neurological diseases by targeting fundamental pathways underlying axon degeneration and neuroimmune regulation to preserve neuronal integrity.
VISIT SITE
PLEXIUM
Plexium is focused on the identification of E3 ligase modulating small molecules to treat cancer and neurodegenerative diseases. Plexium’s platform allows screening for molecular-glue degraders to be conducted via massively high throughput cell-based assays utilizing DNA-encoded libraries.
VISIT SITE
REVOLUTION MEDICINES
Revolution Medicines is an innovative and dynamic organization of expert cellular, structural and computational biologists, medicinal and synthetic chemists, pharmacologists, engineers and business executives working together to discover and develop new medicines for cancer patients.
VISIT SITE
SYNTHEKINE
Synthekine is focused on discovery and developing best in class cytokine therapeutics. The company is generating an array of “synthetic” cytokines and will deploy these unique molecules to tune the immune system in new and interesting ways for the potential treatment of a range of diseases, from cancer to autoimmune disorders.
VISIT SITE
TENAYA THERAPEUTICS
Tenaya is focused on creating therapeutics for heart failure patients. Tenaya seeks to address heart disease through three distinct and multi-modality platforms: a Regeneration Platform, a Gene Therapy Platform, and a Precision Medicine Platform.
VISIT SITE
RAPT THERAPEUTICS
RAPT Therapeutics (formerly FLX Bio) aims to conquer cancer and inflammatory disease in our lifetime. RAPT is fully focused on developing oral therapeutics that intelligently target key drivers of the immune system to transform the treatment of cancer and inflammation, and improve and empower countless lives.
VISIT SITE
RIBON THERAPEUTICS
Ribon Therapeutics is a biotech company focused on developing first-in-class therapeutics targeting monoADP-ribosylating PARPs for cancer.
VISIT SITE
KALLYOPE
Kallyope is dedicated to unlocking the therapeutic potential of the gut-brain axis. Kallyope integrates advanced technologies in sequencing, bioinformatics, neural imaging, cellular and molecular biology, and human genetics to provide an understanding of gut-brain biology that leads to transformational therapeutics to improve human health.
VISIT SITE
NEURONA THERAPEUTICS
Neurona is a cell therapy company focused on the discovery and development of disease-altering treatments for intractable neuropsychiatric disorders. The company seeks to become an industry leader in the neural stem cell field with multiple therapeutic product candidates.
VISIT SITE
ORIC PHARMACEUTICALS
ORIC is a small molecule oncology company focused on combating the growing resistance problem to current molecularly targeted drugs.
VISIT SITE
NGM BIO
NGM Bio is a research-driven, clinical stage biopharmaceutical company with a drug discovery platform that has generated a pipeline of first-in-class biologic development candidates.
VISIT SITE
NURIX
Nurix is focused on discovering and developing therapies that modulate the ubiquitin proteasome system (UPS) for the treatment of a broad range of human disorders, most notably cancer.
VISIT SITE
ARAGON PHARMACEUTICALS
Aragon is creating a new class of nuclear receptor targeting drugs that overcome the biology of hormone resistant cancers. Aragon was acquired by Johnson & Johnson in August 2013 for up to $1B.
VISIT SITE
ARCUS BIOSCIENCES
Arcus Biosciences is an oncology company researching adaptive immunity and innate immunity to discover drugs with broad applicability in combination therapies.
VISIT SITE
CARMOT THERAPEUTICS
Carmot is a clinical-stage company dedicated to the discovery and development of innovative medicines. Using Chemotype Evolution, a transformative, patented drug discovery approach, Carmot has developed a portfolio of drug candidates in metabolic disease and oncology.
VISIT SITE
CONSTELLATION PHARMACEUTICALS
Constellation is a pioneer in the discovery and development of novel therapeutics that target the writer, reader and eraser classes of epigenetic regulators and modulate gene expression in a more selective manner. Constellation was acquired by MorphoSys on June 2, 2021 for $1.7B.
VISIT SITE
EXONICS THERAPEUTICS
Exonics discovers and develops medicines for the treatment of neuromuscular diseases. The Company develops gene editing technologies like CRISPR/Cas9 to permanently correct the majority of Duchenne muscular dystrophy mutations. Exonics was acquired by Vertex on June 6, 2019 for up to $1B.
VISIT SITE
FLEXUS BIOSCIENCES
Flexus was founded with the mission to create new cancer therapeutics through the innovative application of unexploited insights in immunology. Flexus Biosciences was acquired by Bristol-Myers Squibb in April 2015 for $1.3B.
VISIT SITE
GRITSTONE BIO
Gritstone’s goal is to develop groundbreaking immunotherapies for cancers and infectious diseases. The Company's approach focuses on generating a therapeutic immune response in these patients by unleashing the natural power of a patient’s immune system to recognize and destroy tumors or virally-infected cells.
VISIT SITE
IMMUNE DESIGN
Immune Design is an immunotherapy oncology company focused on engineering technologies to activate the immune system’s natural ability to fight disease. Immune Design was acquired by Merck in February 2019 for $0.3B.
VISIT SITE
PELOTON THERAPEUTICS
Peloton Therapeutics is advancing a first-in-class discovery and development pipeline in oncology, comprising several well-differentiated small-molecule programs. Peloton was acquired by Merck in May 2019 for up to $2.35B.
VISIT SITE
SERAGON PHARMACEUTICALS
Seragon is focused on developing new treatments for estrogen-driven cancers based on its Selective Estrogen Receptor Degrader (SERD) platform. Seragon was acquired by Genentech, a member of the Roche Group, in August 2014 for $0.8B.
VISIT SITE
(Does not include inactive companies with minimal return to the Portfolio. The portfolio companies presented on this site are being provided for discussion and illustrative purposes only. Any portfolio company or investment cited on this page may or may not be in the portfolio of a current fund managed by The Column Group. They should not be considered a recommendation to investment in any financial instrument and they do not depict the risks associated with each investment. Further, past performance is no guarantee of future results.)
